Portal de Periódicos da CAPES

Effects of Pretransplantation Treatment With Rituximab on Outcomes of Autologous Stem-Cell Transplantation for Non-Hodgkin's Lymphoma

2004; Lippincott Williams & Wilkins; Volume: 22; Issue: 22 Linguagem: Inglês

10.1200/jco.2004.05.035

1527-7755

Amy L. Hoerr, Feng Gao, Josephine Hidalgo, Divya Tiwari, Kristie A. Blum, Vikram Mathews, Douglas R. Adkins, William Blum, Steven M. Devine, Ravi Vij, Lawrence T. Goodnough, John F. DiPersio, H. Jean Khoury,

Chronic Myeloid Leukemia Treatments

To analyze the effects of preautografting treatment with rituximab (R) on stem-cell mobilization, post-transplantation complications, engraftment, disease-free survival, and overall survival in patients with non-Hodgkin's lymphoma (NHL).Single-institution retrospective comparative outcome analysis in a cohort of 273 relapsed chemosensitive NHL patients of whom 127 (47%) received R pretransplantation.R was administered a median of 3 months before autologous transplantation. When compared to the nonrituximab group, R patients were older (56 v 50 years; P < .001), and had delays in post-transplantation platelets recovery (39 v 27 days; P = .001). Pretransplantation R did not affect stem-cell mobilization, post-transplantation early complications, duration of hospitalization, or mortality rates at days 30 and 100. In contrast to patients with low-grade NHL, both disease-free and overall survival rates were significantly better when R was included in the pretransplantation salvage therapy for patients with intermediate-grade NHL.In this large, single-center retrospective analysis, pretransplantation treatment with R was associated with improved survival in patients with intermediate-grade NHL, at the price, however, of a delay in platelet engraftment.